Mimedx (MDXG) Receivables - Net (2010 - 2026)
Mimedx (MDXG) posted Receivables - Net of $56.1 million for Q2 2026, up 0.95% sequentially from $55.6 million in Q1 2026, and down 23.33% YoY from $73.2 million in Q2 2025.
Mimedx (MDXG) Receivables - Net (2010 - 2026) Analysis & Trends
Mimedx has reported Receivables - Net for 17 years, with the latest figure at $56.1 million in Q2 2026.
- Quarterly Receivables - Net fell 23.33% year-over-year to $56.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $56.1 million (down 23.33% YoY) and the FY2025 annual result came in at $84.4 million, up 43.16% from the prior year.
- Receivables - Net rose to $56.1 million in Q2 2026 per MDXG's latest filing, from $55.6 million in the prior quarter.
- Over five years, Receivables - Net peaked at $83.6 million in Q3 2025 and troughed at $39.1 million in Q1 2022.
- A 5-year average of $56.8 million and a median of $56.1 million in 2024 frame the typical range for Receivables - Net.
- The sharpest annual moves came in 2025 and 2026: Receivables - Net jumped 47.2% in 2025, then fell 23.33% in 2026.
- Over 5 years, Receivables - Net stood at $46.9 million in 2022, then increased by 21.65% to $57.0 million in 2023, then increased by 3.41% to $59.0 million in 2024, then advanced by 28.4% to $75.7 million in 2025, then retreated by 25.9% to $56.1 million in 2026.
- According to Business Quant data, Receivables - Net over the past three periods registered $56.1 million, $55.6 million, and $75.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Mimedx | 622.24 Mn | 486.40 Mn | 44.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.10 Mn |
| Jun 30, 2026 | 56.10 Mn |
| Mar 31, 2026 | 55.57 Mn |
| Mar 31, 2026 | 55.57 Mn |
| Dec 31, 2025 | 75.71 Mn |
| Dec 31, 2025 | 75.71 Mn |
| Sep 30, 2025 | 83.60 Mn |
| Sep 30, 2025 | 83.60 Mn |
| Jun 30, 2025 | 73.17 Mn |
| Jun 30, 2025 | 73.17 Mn |
| Mar 31, 2025 | 66.16 Mn |
| Mar 31, 2025 | 66.16 Mn |
| Dec 31, 2024 | 58.96 Mn |
| Dec 31, 2024 | 58.96 Mn |
| Sep 30, 2024 | 56.80 Mn |
| Sep 30, 2024 | 56.80 Mn |
| Jun 30, 2024 | 56.07 Mn |
| Jun 30, 2024 | 56.07 Mn |
| Mar 31, 2024 | 60.28 Mn |
| Mar 31, 2024 | 60.28 Mn |